Clinical Trial Search

Primary: Change From Baseline in 0 to 4 Hours Post-dose Weighted Mean Heart Rate at Day 42, Derived From Electrocardiograms (ECGs) — 0.688; -1.557 Beats per minute (bpm)

Primary: Overall Survival (OS) — 87.3; 82 percentage of participants

Primary: Percent Change From Baseline to Weeks 24 and 48 in Lumbar Spine BMD — 14.4; 5.5; 15.9; 7.1 Percent change from baseline — p=<0.001

Primary: Progression-free Survival (PFS) - Initial Treatment Period — 2.9; 3.0; 2.8 Months — p=<0.0001

Primary: Percent Change in Lumbar Spine Bone Mineral Density — 5.6; 0.2 percentage of change — p=< 0.01

Primary: Complete Response Rate — 0; 13 percentage of participants

Primary: Change From Baseline in Drinking Quantity and Frequency Using Drinks Per Week at Week 12 — 42.07; 56.67; 41.20; 9.16 drinks/week

Primary: Number of Participants With Any Adverse Event (AE) Considered to be Related to Study Treatment — 28; 5 Participants

Primary: Percentage of Heavy Drinking Days — 45.0; 50.6; 44.0; 5.2 percentage of heavy drinking days

Primary: MS Walking Scale-12 (MSWS-12) — 72.6; 82.2 units on a scale — p=0.84

Primary: Evaluate the Objective Response Rate of Patients Treated With Taxotere/Carboplatin With or Without Herceptin Preoperatively. — 13; 8; 33; 54 participants

Primary: Maximal Change in Forced Expiratory Volume in One Second (FEV1) From Baseline (Pre-dose on Day 1) in Combination With Short Acting Bronchodialator (Salbutamol or…

Primary: Percentage of Participants in Clinical Remission at Week 12 — 2.7; 11.3; 16.7; 15.5 percentage of participants — p=0.0213

Primary: Change in Pain Scores From 0-30 Minutes on a Visual Analog Scale (VAS) — 1.38; 1.22 units on a scale — p=0.674

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg